|
Buy (2.83 out of 4)
26th percentile
|
|
|
SLIDESHOW: Best Dividend Paying Stocks Analysts Like in the Dow
By Dividend Channel Staff, updated Tuesday, March 19, 8:57 AM
#10. Amgen Inc (NASDAQ:AMGN) — Ranked #21 in the DJIA by Analysts, 3.35% Dividend Yield Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
Name: |
Amgen Inc |
Stock buyback: |
AMGN buyback |
Website: |
www.amgen.com |
Sector: |
Biotechnology |
Number of ETFs Holding AMGN: |
134 (see which ones) |
Total Market Value Held by ETFs: |
$23,054,248,081.69 |
Total Market Capitalization: |
$145,523,000,000 |
% of Market Cap. Held by ETFs: |
15.84% |
|
Open the Dividend Channel AMGN Page (in a new window) »
|
|
|